Earlier this year, we took a look at the emerging market for GLP-1 weight loss medications, especially the new D2C disruptors like Weight Watchers' Sequence. One of our major takeaways was that the surge of interest in these drugs is both a threat and opportunity for LHS with existing weight management programs. In the piece, we put out a call for LHS to share how they are working GLP-1s into their programs and leaders from Vanderbilt University Medical Center graciously agreed to share more about their strategy.